ArticleEndocrine2026
Efficacy, safety and predictors of response to minimally invasive treatments of the thyroid: a prospective study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMinimally invasive techniques (MITs), including percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA), are effective non-surgical options for benign thyroid nodules (BTN). However, predictors of response and technical determinants remain incompletely defined.
methodsWe conducted a prospective single-center study including 120 BTNs (45 PEI, 75 RFA) treated between 2022 and 2025, with 12-month follow-up. The primary objective of this study was to identify clinical and procedural predictors of treatment response following MITs for BTNs. The primary outcome measure was the 12-month volume reduction ratio (VRR). Secondary endpoints included changes in cosmetic and symptomatic scores, thyroid function in autonomously functioning nodules (AFTN), and safety outcomes.
resultsBaseline mean nodule volume was 22.06 mL SD 14.52, cosmetic score 3.39 SD 0.93, and dysphagia score 3.33 SD 1.8. At 12 months, mean VRR was 84.24% overall, 95.9% after PEI, and 77.4% after RFA, achieving therapeutic success in 96.67% of cases (p < 0.001). In AFTN, MITs, comprising 3 predominantly cystic nodules treated with PEI and 10 solid nodules treated with RFA, achieved a mean VRR of 88.17%, with TSH increasing from 0.12 SD 0.13 to 2.17 SD 2.47 mIU/L; 76.9% of these patients were on antithyroid medication prior to ablation, all discontinued post-procedure. Baseline nodule volume independently predicted VRR (β = - 0.237; p = 0.014), while energy density (kcal/mL) predicted RFA efficacy (β = 1.416; p = 0.047). All adverse events were mild and transient, including local pain (27.5%), transient dysphonia (6.7%), and transient cough or vagal reaction. No permanent complications occurred.
conclusionPEI and RFA are safe and effective minimally invasive options for BTN, achieving durable volume reduction with improved clinical outcomes. Smaller nodules and higher energy delivery/ml predict optimal response.
Indexed as
Identifiers
42706390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.